Create the future of medicine.
CELLINK is creating the future of medicine by providing technologies, products and services to create, understand, and master biology.
1,800 + Labs
In 2016, we commercialized the world’s first universal bioink—an innovation 8 years in the making—which spurred our rapid rise to becoming the world’s leading bioprinting company. Fast-forward to 2020, after three successful acquisitions and several high-profile product launches, we are much more than a bioprinting company. We have embraced the emerging bio-convergence revolution, which is leveraging synergistic breakthroughs in the life sciences and technology to meet the world’s growing healthcare needs. By combining advances in biology, engineering, big data and AI, we are now the top bio-convergence company in the world, creating the future of medicine.
Four years. 1,800 scientists. 55 countries.
In 2016, CELLINK commercialized the world’s first bioink, a biomaterial innovation eight years in the making. That milestone was the first of many along the company’s four-year journey to become the world’s leading bioprinting company with systems used to optimize cell-based applications.
Our products have been adopted by researchers around the world in more than 55 countries, 18 of the top 20 global pharmaceutical companies, close to 1,000 laboratories, and have been cited in over 90 publications on tissue engineering, biomaterials, and cell culturing applications.
Photo: Bert Leandersson/Liljewall
Today, CELLINK is a publicly listed, global company working to maximize the impact of groundbreaking life-science research through the transfer and commercialization of scientific breakthroughs into accessible, state-of-the-art technologies that disrupt entire industries.
We leverage the talents and enthusiasm of more than 330 engineers, scientists, financial experts and sales and marketing specialists to nurture the research and development of innovative life-science products and technologies for a wide range of applications and industries.
transforming ideas into revolutionary products
With a combination of persistence, passion and innovation, we catalyzed and accelerated the genesis of the bioprinting industry by bringing bioprinting technologies from the lab to the clinic with unprecedented speed. In doing so, we transformed CELLINK into a globally recognized pioneer of 3D cell cultivation systems in pharmaceutical research and drug development.
Expanding product portfolio
By working closely with our customers around the world, we leverage our market awareness and direct sales channels to bring the benefits of breakthrough research to a number of cell-based applications. Our successful development of an impressive product portfolio of 80 patented and patent-pending technologies across five companies has made us the trusted partner with the acumen, strategy and assets to easily navigate rapidly evolving markets.
While aiming to “Create the future of medicine”, we have focused on the three application areas that are essential to cell culturing: Bioprinting, Analysis and Liquid handling/bioprocessing. At the same time, we have made significant progress in research and development and have acquired complementary technologies within these fields to provide scientists with complete workflows supported by our dedicated scientists and technicians.
We are growing!
As we apply our industry-leading expertise, persistence and passion to drive advancements in all aspects of bioprinting, from bioinks to bioprinters, we are also growing our business. We are now including industrial solutions to our offerings in order to give our collaborators complete optimized workflows from early-stage development to large-scale manufacturing.
widening the range of areas
This is an exciting time for CELLINK as we continue applying our industry-leading expertise, persistent work ethic and passion to drive advancement in bioprinting and beyond. We are looking forward to integrating our new core capabilities and widening the range of areas where users can expect CELLINK-quality results.